Abstract 5340
Background
HGSOC is known to demonstrate diverse molecular heterogeneity. It is unclear whether the tumor microenvironments such as the stromal components in the extracellular matrix (ECM) also exist heterogeneity.
Methods
As a proof-of concept study, characterization of collagen patterns was performed on 60 unstained formalin-fixed paraffin embedded (FFPE) HGSOC samples (three sections from each of the 20 patients). Each section with 5 micron thickness and a minimum tumour surface area of 40 mm2 were scanned by using a multiphoton imaging system (Genesis 200, HistoIndex) following deparaffinization. Parameters including Collagen Area Ratio (CAR), Collagen Fiber Density (CFD), Collagen Reticulation Index (CRI), Collagen Fiber Number (CFN), Collagen Fiber Thickness (CFT), and Collagen Fiber Length (CFL) were analysed. Unsupervised hierarchical clustering analysis was performed.
Results
Unsupervised hierarchical clustering of the collagen parameters revealed four distinct patterns in HGSOC samples. G1 tumors consisted of long and thick collagen fibers with high CFT and CFL. G2 tumors were low in all the collagen parameters, suggesting a relatively “clean” stromal without collagen deposition. G3 tumors consisted of dense collagen fibers with high CRI suggestive of extensive cross alignment among the fibers. G4 tumors were high in CFN and low in CRI, CFT and CFL, suggesting a stroma loaded with high amount of thin and short collagen fibers without cross alignment.The collagen patterns were not exclusive for specific organ sites (ovary, fallopian tube, other metastatic sites) except that the collagen pattern from the omental metastases were mainly G2 (10/18; 55.6%) and G4 (6/18; 33.3%).
Conclusions
The stromal component in the ECM of HGSOC can be successfully quantitated by the multi-photon imaging technology on unstained FFPE sections. The collagen component exhibited significant heterogeneity in terms of the number, thickness, length, and reticulation patterns. The contribution of different collagen patterns to clinical outcomes and the correlation with known molecular subtypes in HGSOC warrants further investigation in larger cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Singapore.
Funding
National Medical Research Council of Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract